TransCode Therapeutics, Inc. Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

TransCode Therapeutics, Inc. is a biotechnology research company based in Newton, Massachusetts, with 11 to 50 employees and a website at transcodetherapeutics.com. Its core approach uses a proprietary delivery platform called TTX to transport targeted therapeutics to cancer cells, with the lead candidate TTX-MC138 designed to target microRNA-10b, described as a master regulator of metastatic cell viability across multiple cancers. TransCode positions itself as a clinical-stage oncology company pursuing RNA and immuno-oncology therapeutics and maintains a rapidly expanding platform of drug candidates for various tumor indications. The company has licensed three oncolytic adenovirus candidates—UIO-524, UIO-525, and UIO-526—from Unleash Immuno Oncolytics, and has entered into a sponsored research agreement with Michigan State University. Public information indicates the company trades on Nasdaq under the ticker RNAZ and appointed Anna Moore as Chair of its Scientific Advisory Board in April 2026.

Get verified TransCode Therapeutics, Inc. emails free

Company overview Employee directory